Everyday Erinyes #257

 Posted by at 10:24 am  Politics
Mar 132021
 

Experts in autocracies have pointed out that it is, unfortunately, easy to slip into normalizing the tyrant, hence it is important to hang on to outrage. These incidents which seem to call for the efforts of the Greek Furies (Erinyes) to come and deal with them will, I hope, help with that. As a reminder, though no one really knows how many there were supposed to be, the three names we have are Alecto, Megaera, and Tisiphone. These roughly translate as “unceasing,” “grudging,” and “vengeful destruction.”

on this day I just cannot bring myself to put up anything negative. So I am sharing a lemons-to-lemonade story about how the CoViD pandemic resulted in ad viance which will go on being useful way after the pandemic is over. I am 75, and I have in my lifetime seen numerous medical advances which felt miraculous. But I have also seen many more years of waiting for them. To be talking now in terms , not of years, but of months, for a vaccine against a disease which somehow came out of nowhere is truly amazing. And with virtually every such advance come unsought advances. That is what we are going to look at today.
================================================================

3 medical innovations fueled by COVID-19 that will outlast the pandemic

Gene-based vaccines had never been approved for humans before the coronavirus pandemic.
Juan Gaertner/Science Photo Library via Getty Images

Deborah Fuller, University of Washington; Albert H. Titus, University at Buffalo, and Nevan Krogan, University of California, San Francisco

A number of technologies and tools got a chance to prove themselves for the first time in the context of COVID-19. Three researchers working in gene-based vaccines, wearable diagnostics and drug discovery explain how their work rose to the challenge of the pandemic, and their hopes that each technology is now poised to continue making big changes in medicine.


Genetic vaccines

Deborah Fuller, Professor of Microbiology, University of Washington

Thirty years ago, researchers for the first time injected mice with genes from a foreign pathogen to produce an immune response. Like many new discoveries, these first gene-based vaccines had their ups and downs. Early mRNA vaccines were hard to store and didn’t produce the right type of immunity. DNA vaccines were more stable but weren’t efficient at getting into the cell’s nucleus, so they failed to produce sufficient immunity.

Researchers slowly overcame the problems of stability, getting the genetic instructions where they needed to be and making them induce more effective immune responses. By 2019, academic labs and biotechnology companies all over the world had dozens of promising mRNA and DNA vaccines for infectious diseases, as well as for cancer in development or in phase 1 and phase 2 human clinical trials.

When COVID-19 struck, mRNA vaccines in particular were ready to be put to a real-world test. The 94% efficacy of the mRNA vaccines surpassed health officials’ highest expectations.

DNA and mRNA vaccines offer huge advantages over traditional types of vaccines, since they use only genetic code from a pathogen – rather than the entire virus or bacteria. Traditional vaccines take months, if not years, to develop. In contrast, once scientists get the genetic sequence of a new pathogen, they can design a DNA or mRNA vaccine in days, identify a lead candidate for clinical trials within weeks and have millions of doses manufactured within months. This is basically what happened with the coronavirus.

Gene-based vaccines also produce precise and effective immune responses. They stimulate not only antibodies that block an infection, but also a strong T cell response that can clear an infection if one occurs. This makes these vaccines better able to respond to mutations, and it also means they could be capable of eliminating chronic infections or cancerous cells.

The hopes that gene-based vaccines could one day provide a vaccine for malaria or HIV, cure cancer, replace less effective traditional vaccines or be ready to stop the next pandemic before it gets started are no longer far-fetched. Indeed, many DNA and mRNA vaccines against a wide range of infectious diseases, for treatment of chronic infections and for cancer are already in advanced stages and clinical trials. As someone who has been working on these vaccines for decades, I believe their proven effectiveness against COVID-19 will usher in a new era of vaccinology with genetic vaccines at the forefront.


A person wearing a smart watch.
Smartwatches and other wearable technologies allow users to capture more continuous health data than ever before.
Pixabay

Wearable tech and early illness detection

Albert H. Titus, Professor of Biomedical Engineering, University at Buffalo

During the pandemic, researchers have taken full advantage of the proliferation of smartwatches, smart rings and other wearable health and wellness technology. These devices can measure a person’s temperature, heart rate, level of activity and other biometrics. With this information, researchers have been able to track and detect COVID-19 infections even before people notice they have any symptoms.

As wearable usage and adoption grew in recent years, researchers began studying the ability of these devices to monitor disease. However, although real-time data collection was possible, previous work had focused primarily on chronic diseases.

But the pandemic both served as a lens to focus many researchers in the field of health wearables and offered them an unprecedented opportunity to study real-time infectious disease detection. The number of people potentially affected by a single disease – COVID-19 – at one time gave researchers a large population to draw from and to test hypotheses on. Combined with the fact that more people than ever are using wearables with health monitoring functions and that these devices collect lots of useful data, researchers were able to try to diagnose a disease solely using data from wearables – an experiment they could only dream of before.

Wearables can detect symptoms of COVID-19 or other illnesses before symptoms are noticeable. While they have proved to be capable of detecting sickness early, the symptoms wearables detect are not unique to COVID-19. These symptoms can be predictive of a number of potential illnesses or other health changes, and it is much harder to say what illness a person has versus simply saying they are sick with something.

Moving into the post-pandemic world, it’s likely that more people will incorporate wearables into their lives and that the devices will only improve. I expect the knowledge researchers have gained during the pandemic on how to use wearables to monitor health will form a starting point for how to handle future outbreaks – not just of viral pandemics, but potentially of other events such as food poisoning outbreaks and seasonal flu episodes. But since wearable tech is concentrated within pockets of affluent and younger populations, the research community and society as a whole must simultaneously address the disparities that exist.


A map showing proteins connections.
Every place that a coronavirus protein interacts with a human protein is a potential druggable site.
QBI Coronavirus Research Group, CC BY-ND

A new way to discover drugs

Nevan Krogan, Professor of Cellular Molecular Pharmacology and Director of the Quantitative Biosciences Institute, University of California, San Francisco

Proteins are the molecular machines that make your cells function. When proteins malfunction or are hijacked by a pathogen, you often get disease. Most drugs work by disrupting the action of one or several of these malfunctioning or hijacked proteins. So a logical way to look for new drugs to treat a specific disease is to study individual genes and proteins that are directly affected by that disease. For example, researchers know that the BRCA gene – a gene that protects your DNA from being damaged – is closely related to the development of breast and ovarian cancer. So a lot of work has focused on finding drugs that affect the function of the BRCA protein.

However, single proteins working in isolation are usually not solely responsible for disease. Genes and the proteins they encode are part of complicated networks – the BRCA protein interacts with tens to hundreds of other proteins that help it perform its cellular functions. My colleagues and I are part of a small but growing field of researchers who study these connections and interactions among proteins – what we call protein networks.

For a few years now, my colleagues and I have been exploring the potential of these networks to find more ways drugs could ameliorate disease. When the coronavirus pandemic hit, we knew we had to try this approach and see if it could be used to rapidly find a treatment for this emerging threat. We immediately started mapping the extensive network of human proteins that SARS-CoV-2 hijacks so it can replicate.

Once we built this map, we pinpointed human proteins in the network that drugs could easily target. We found 69 compounds that influence the proteins in the coronavirus network. 29 of them are already FDA-approved treatments for other illnesses. On Jan. 25 we published a paper showing that one of the drugs, Aplidin (Plitidepsin), currently being used to treat cancer, is 27.5 times more potent than remdesivir in treating COVID-19, including one of the new variants The drug has been approved for phase 3 clinical trials in 12 countries as a treatment for the new coronavirus.

But this idea of mapping the protein interactions of diseases to look for novel drug targets doesn’t apply just to the coronavirus. We have now used this approach on other pathogens as well as other diseases including cancer, neurodegenerative and psychiatric disorders.

These maps are allowing us to connect the dots among many seemingly disparate aspects of single diseases and discover new ways drugs could treat them. We hope this approach will allow us and researchers in other areas of medicine to discover new therapeutic strategies and also see whether any old drugs might be repurposed to treat other conditions.

[Understand new developments in science, health and technology, each week. Subscribe to The Conversation’s science newsletter.]The Conversation

Deborah Fuller, Professor of Microbiology, School of Medicine, University of Washington; Albert H. Titus, Professor of Biomedical Engineering, University at Buffalo, and Nevan Krogan, Professor and Director of Quantitative Biosciences Institute & Senior Investigator at the Gladstone Institutes, University of California, San Francisco

This article is republished from The Conversation under a Creative Commons license. Read the original article.

================================================================
AMT, just take the day (and the week) off. Dance if you like. Here’s some dance music just for you –

(We mere humans can put it into another tab or window to listen if the picture going up and down makes us dizzy.)

The Furies and I will be back.

Share

  6 Responses to “Everyday Erinyes #257”

  1. I found the section of ‘Wearable tech and early illness detection’ most interesting.
    And educational. imho. 
     
    Lots of info, and how the research is on-going. Amazing. 
    An educational and comprehensive post re: Covid-19. 

    Thank you, Joanne (and Erinyes) for post. 

  2. Thanks for all the serendipities related to our Covid vaccines and treatments Joanne!  I know of one local hospital that used digital monitoring along with phone calls a couple times a day after ER visit of patients who were not yet severe to identify if/when O2 levels dictated an admission during the winter surge to help preserve hospital bed capacity–might have made all the difference to our area’s capacity.

  3. Great post Joanne.
    I appreciate the information you posted regarding Covid-19 and all of it’s variants. There’s so much to learn.
    It’s good knowing that they are trying their best to keep on top of the life killing virus. Heard last night that Italy and Germany are facing another lockdown, due to the new Covid-19 variants. 
    Hopefully in the coming months they’ll have it under control and will find a way that they can totally prevent this type of pandemic from ever happening again.
    Last night on the news they announced that Italy and Germany are facing another lockdown, due to the new Covid-19 variants. 
    I personally will be getting my second Pfizer vaccination tomorrow morning. I’m a little concern about reading that there might be more side effects from the second shot.
    Thanks Joanne

  4. Thanks again for a very educational Erinyes, Joanne. Its good to learn that the science around COVId also brought some new discoveries along which will benefit mankind in future years. As the Dutch say: Luck Comes With Unluck which translates into Every Dark Cloud Has Its Silver Lining, I suppose.

    After a year of COVID, we can all do with some positive news. 

  5. Undoubtedly this will be included in the Pantheon of “Lemons-to-Lemonade” posts.

    But I have to admit, as wonderful as it is – it really requires a second (and maybe third) reading to fully digest it!

    You’ve outdone yourself!

  6. thank you and medical science has really amazingly developed new technology…..we are fortunate in that sense to live today…..

Sorry, the comment form is closed at this time.